Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter?
- 2 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (7), 797-806
- https://doi.org/10.1080/17512433.2020.1783248
Abstract
With the goal of improving the affordability of medicines, governments across the globe have instituted various forms of price controls. Since 2013, India has been regulating the prices of drugs included in its national list of essential medicines (NLEM). Here we evaluate the cost variations among available cardiovascular drugs and perform cost-analysis comparing essential and non-essential drugs. Data on listed prices of selected cardiovascular drugs – essential (NLEM) and non-essential (NNLEM) – were sourced from multiple drug information compendia. Price of medications was calculated in cost-per-defined-daily-dose (DDD)-units and NLEM vs. NNLEM drugs were compared. Regression analysis was used to explore the determinants of percentage cost variation (PCV) of drugs. The median-cost/DDD of essential medicines was lower as compared to non-essential ones for all therapeutic drug classes, with greatest difference observed for antianginals and least for heart failure medicines. There were substantial cost variations with values in excess of 1000% for six medicines, all being essential. The regression analysis failed to demonstrate a significant effect of essentiality on PCV (β = 0.19, P = 0.314). Our analyses demonstrate considerable cost variations for some essential cardiovascular medicines. Given the need for prolonged and often, lifelong-treatment, there is significant potential for cost savings based on chosen brand, highlighting the need for patient as well as prescriber education.Keywords
This publication has 30 references indexed in Scilit:
- Switch over from intravenous to oral therapy: A concise overviewJournal of Pharmacology and Pharmacotherapeutics, 2014
- NCDs: a challenge to sustainable human developmentThe Lancet, 2013
- Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implicationsJournal of Comparative Effectiveness Research, 2012
- A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income CountriesPLOS ONE, 2011
- Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI dataBMC Cardiovascular Disorders, 2010
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- International comparison of generic medicine pricesCurrent Medical Research and Opinion, 2007
- Price Competition in Pharmaceuticals: The Case of Anti‐infectivesEconomic Inquiry, 2004
- International Differences in Drug PricesAnnual Review of Public Health, 2004
- Entry and Competition in Concentrated MarketsJournal of Political Economy, 1991